ALPROLIX.com
Hospitals & Physicians Clinics · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
225 2nd Ave, Waltham, Massachusetts, 024...Website
www.alprolix.comRevenue
$25.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
2
2
1
1
About ALPROLIX.com
Learn about ALPROLIX, a therapy regimen for the treatment of hemophilia B that uses Fc Fusion to keep Factor IX circulating in your bloodstream longerExplore more
ALPROLIX.com Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ALPROLIX.com your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ALPROLIX.com has recently received funding, and reach out quickly before it becomes old news!
Click to see if ALPROLIX.com had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ALPROLIX.com
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ALPROLIX.com launches new products
ALPROLIX.com, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once ALPROLIX.com has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ALPROLIX.com recently announced quarterly report
Check out if ALPROLIX.com is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to ALPROLIX.com
Compare insights from companies similar to ALPROLIX.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ALPROLIX.com is experiencing very low activity levels compared to other companies in the Hospitals & Physicians Clinics sector.
What does this means?
ALPROLIX.com is drawing exceptional interest within the Hospitals & Physicians Clinics industry, suggesting notable developments or strong market momentum, learn more about ALPROLIX.com.
ALPROLIX.com Tech Stack
A closer look at the technologies used by ALPROLIX.com
ALPROLIX.com News & Media
Data presented at ISTH2020 strengthens evidence for both Elocta ® and Alprolix ® in previously untreated patients with haemophilia
Final results from the PUPs A-LONG and PUPs B-LONG studies assessing the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) in previously untreated patients (PUPs) with haemophilia A and B respectively were presented at the ISTH2020 (International Society on Thrombosis and Haemostasis) Virtual Congress, July 12-14. The results were presented jointly by Sobi™ (https://www.sobi.com/) and Sanofi, collaborators in the development and commercialisation of AlprolData to be presented at ISTH Virtual Congress highlights Sobi's commitment to advancing rare haematolog y treatments
Sobi™ (http://www.sobi.com/) will present data at the ISTH Virtual Congress (International Society on Thrombosis and Haemostasis), 12 – 14 July 2020, strengthening evidence for the efficacy and safety of Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa), for haemophilia A and B respectively, as well as pharmacokinetic data on BIVV001 (rFVIIIFc-VWF-XTEN). Data for Doptelet® (avatrombopag) in treatment for thrombocytopenia within Chronic Liver Disease (CLD) and Chronic Immune ThroAt ASH, Extended Half-life Therapies Elocta® and Alprolix® Demonstrate Proven Efficacy and Well-characterised Safety Over Four Years
STOCKHOLM, Dec. 2, 2018 /PRNewswire/ -- Orphan Biovitrum AB (publ) (Sobi™) and Bioverativ Inc., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in haemophilia. The data from both...At ASH, Extended Half-Life Therapies ELOCTATE® and ALPROLIX® Demonstrate Proven Efficacy and Well-Characterized Safety over Four Years
SAN DIEGO--(BUSINESS WIRE)--Bioverativ Inc., a Sanofi company, and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in hemophilia. The data from both studies confirm the established safety and sustained efficacy of ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein], marketed as Elocta® in Europe and the Middle East, and ALPROLIX® [Coagulati
Read more news
Top Hospitals & Physicians Clinics Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALPROLIX.com
Sign Up For FreeTo access detailed company insights
Learn about ALPROLIX, a therapy regimen for the treatment of hemophilia B that uses Fc Fusion to keep Factor IX circulating in your bloodstream longer... Read More
